• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 8-K filed by STERIS plc (Ireland)

    8/1/24 4:31:03 PM ET
    $STE
    Industrial Specialties
    Health Care
    Get the next $STE alert in real time by email
    8-K
    false 0001757898 0001757898 2024-08-01 2024-08-01 0001757898 us-gaap:CommonStockMember 2024-08-01 2024-08-01 0001757898 ste:M2.700SeniorNotesDue2031Member 2024-08-01 2024-08-01 0001757898 ste:M3.750SeniorNotesDue2051Member 2024-08-01 2024-08-01

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM 8-K

     

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d)

    of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): August 1, 2024

     

     

    STERIS plc

    (Exact Name of Registrant as Specified in Charter)

     

     

     

    Ireland   001-38848   98-1455064
    (State or Other Jurisdiction
    of Incorporation)
      (Commission
    File Number)
      (IRS Employer
    Identification No.)

     

    70 Sir John Rogerson’s Quay
    Dublin 2, Ireland
    (Address of Principal Executive Offices)

    +353 1 232 2000

    (Registrant’s Telephone Number, Including Area Code)

    Not Applicable

    (Former name or former address, if changed since last report.)

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class

     

    Trading
    Symbol(s)

     

    Name of each exchange
    on which registered

    Ordinary Shares. $0.001 par value   STE   New York Stock Exchange
    2.700% Senior Notes due 2031   STE/31   New York Stock Exchange
    3.750% Senior Notes due 2051   ST/51   New York Stock Exchange

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     


    ITEM 5.07.

    Submission of Matters to a Vote of Security Holders.

    At the 2024 Annual General Meeting of Shareholders (“Meeting”) of STERIS plc (the “Company”) held on August 1, 2024, shareholders voted on the matters specified below, with the final voting results as specified. According to the final report of the inspector of election, there were 98,853,221 Ordinary Shares of the Company outstanding and entitled to vote at the Meeting. There were present at the Meeting, in person or by proxy, the holders of 92,479,253 Ordinary Shares or 93.55% of the outstanding Ordinary Shares of the Company on the record date, constituting a quorum.

     

    1.

    The shareholders elected the nominees named below to the board of directors of the Company (the “Board”), each for a one-year term, and the results of the vote were as follows:

     

    Nominee

       Votes for      Votes
    against
         Abstentions      Broker
    non-votes
     

    Dr. Esther M. Alegria

         87,479,377        1,303,862        42,599        3,653,415  

    Richard C. Breeden

         84,174,452        4,489,323        162,063        3,653,415  

    Daniel A. Carestio

         87,226,475        1,551,224        48,139        3,653,415  

    Cynthia L. Feldmann

         81,958,610        6,825,562        41,666        3,653,415  

    Christopher S. Holland

         87,619,989        1,164,660        41,189        3,653,415  

    Dr. Jacqueline B. Kosecoff

         84,159,181        4,626,670        39,987        3,653,415  

    Paul E. Martin

         87,629,553        1,148,652        47,633        3,653,415  

    Dr. Nirav R. Shah

         87,607,353        1,176,588        41,897        3,653,415  

    Dr. Mohsen M. Sohi

         81,600,545        7,068,512        156,781        3,653,415  

    Dr. Richard M. Steeves

         88,063,034        685,131        77,673        3,653,415  

     

    2.

    The shareholders approved the proposal to ratify the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the year ending March 31, 2025 by the following votes:

     

    Votes for

         82,980,785  

    Votes against

         9,462,713  

    Abstentions

         35,755  

     

    3.

    The shareholders approved the proposal to appoint Ernst & Young Chartered Accountants as the Company’s statutory auditor under Irish law to hold office until the conclusion of the Company’s next Annual General Meeting by the following votes:

     

    Votes for

         83,078,617  

    Votes against

         9,364,485  

    Abstentions

         36,151  

     

    4.

    The shareholders approved the proposal to authorize the Board of the Company or the Audit Committee of the Board to determine the remuneration of Ernst & Young Chartered Accountants as the Company’s statutory auditor under Irish law by the following votes:

     

    Votes for

         91,001,119  

    Votes against

         1,438,875  

    Abstentions

         39,259  

     

    5.

    The shareholders approved the proposal to approve, on a non-binding advisory basis, the compensation of the Company’s named executive officers as disclosed pursuant to the disclosure rules of the Securities and Exchange Commission, including the Compensation Discussion and Analysis and the tabular and narrative disclosure contained in the Company’s proxy statement dated June 12, 2024, by the following votes:

     

    Votes for

         82,283,019  

    Votes against

         6,478,744  

    Abstentions

         64,075  

    Broker non-votes

         3,653,415  


    6.

    The shareholders approved the proposal to the renewal of the Board’s authority to issue authorized but unissued shares under Irish law, by the following votes:

     

    Votes for

         91,164,220  

    Votes against

         1,255,421  

    Abstentions

         59,612  

     

    7.

    The shareholders approved the proposal to approve the renewal of the Board’s authority to opt-out of statutory pre-emption rights under Irish law regarding the issuance of shares for cash, by the following votes:

     

    Votes for

         84,584,590  

    Votes against

         7,683,370  

    Abstentions

         211,293  


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

    STERIS plc
    By  

    /s/ J. Adam Zangerle

      J. Adam Zangerle
      Senior Vice President, General Counsel and Company Secretary

    Dated: August 1, 2024

    Get the next $STE alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $STE

    DatePrice TargetRatingAnalyst
    7/15/2025$276.00Equal-Weight → Overweight
    Morgan Stanley
    5/29/2025$263.00Hold
    Jefferies
    10/24/2024$230.00 → $260.00Neutral → Overweight
    Piper Sandler
    2/6/2024$253.00Overweight
    KeyBanc Capital Markets
    5/30/2023$206.00Equal-Weight
    Morgan Stanley
    4/14/2023$215.00 → $197.00Overweight → Neutral
    Piper Sandler
    9/23/2022Buy → Hold
    Needham
    7/14/2022$240.00Overweight
    Piper Sandler
    More analyst ratings

    $STE
    SEC Filings

    View All

    SEC Form 10-Q filed by STERIS plc (Ireland)

    10-Q - STERIS plc (0001757898) (Filer)

    2/6/26 4:04:07 PM ET
    $STE
    Industrial Specialties
    Health Care

    STERIS plc (Ireland) filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - STERIS plc (0001757898) (Filer)

    2/4/26 4:32:07 PM ET
    $STE
    Industrial Specialties
    Health Care

    SEC Form 144 filed by STERIS plc (Ireland)

    144 - STERIS plc (0001757898) (Subject)

    11/18/25 4:46:18 PM ET
    $STE
    Industrial Specialties
    Health Care

    $STE
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    STERIS Announces Financial Results for Fiscal 2026 Third Quarter

    Total revenue from continuing operations increased 9%; constant currency organic revenue grew 8% As reported EPS from continuing operations increased to $1.96; adjusted EPS increased to $2.53Fiscal 2026 outlook maintained DUBLIN, IRELAND, Feb. 04, 2026 (GLOBE NEWSWIRE) -- STERIS plc (NYSE:STE) ("STERIS" or the "Company") today announced financial results for its fiscal 2026 third quarter ended December 31, 2025. Total revenue from continuing operations for the third quarter of fiscal 2026 increased 9% to $1.5 billion compared with $1.4 billion in the third quarter of fiscal 2025. Constant currency organic revenue growth from continuing operations for the third quarter was 8%. "We are pl

    2/4/26 4:30:00 PM ET
    $STE
    Industrial Specialties
    Health Care

    STERIS Announces Dividend of $0.63 per share

    DUBLIN, IRELAND, Jan. 28, 2026 (GLOBE NEWSWIRE) -- STERIS plc (NYSE:STE) ("STERIS" or the "Company") announced today that the Company will distribute a quarterly dividend of $0.63 per share. The dividend is payable on March 19, 2026, to shareholders of record at the close of business on February 17, 2026.   Additional information about the U.S. tax treatment of dividends, including required Forms 8937, is available at www.steris-ir.com. STERIS is a leading global provider of products and services that support patient care with an emphasis on infection prevention. WE HELP OUR CUSTOMERS CREATE A HEALTHIER AND SAFER WORLD by providing innovative healthcare and life science products and serv

    1/28/26 4:30:00 PM ET
    $STE
    Industrial Specialties
    Health Care

    STERIS to Host a Conference Call for Fiscal 2026 Third Quarter Results on February 5, 2026

    DUBLIN, IRELAND, Jan. 21, 2026 (GLOBE NEWSWIRE) -- STERIS plc (NYSE:STE) ("STERIS" or the "Company") announced today that it will host a conference call to discuss its fiscal 2026 third quarter results at 9:00 a.m. ET on February 5, 2026. The conference call can be heard live at www.steris-ir.com or via phone by dialing 1-833-535-2199 in the United States or 1-412-902-6776 internationally, then asking to join the conference call for STERIS plc. A press release detailing financial results will be issued after the U.S. market closes on February 4, 2026. For those unable to listen to the conference call live, a replay will be available beginning at 12:00 p.m. ET on February 5, 2026, either

    1/21/26 4:30:00 PM ET
    $STE
    Industrial Specialties
    Health Care

    $STE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    VP, Chf. Comp. & Quality Offc. Mcgowan Lindsey was granted 798 units of Ordinary Shares, increasing direct ownership by 19% to 5,028 units (SEC Form 4)

    4 - STERIS plc (0001757898) (Issuer)

    1/6/26 4:32:31 PM ET
    $STE
    Industrial Specialties
    Health Care

    New insider Mcgowan Lindsey claimed ownership of 4,478 units of Ordinary Shares (SEC Form 3)

    3 - STERIS plc (0001757898) (Issuer)

    1/6/26 4:31:17 PM ET
    $STE
    Industrial Specialties
    Health Care

    Sr. VP and GM, Life Sciences Madsen Julia exercised 5,008 units of Ordinary Shares at a strike of $128.22 and sold $1,312,096 worth of Ordinary Shares (5,008 units at $262.00) (SEC Form 4)

    4 - STERIS plc (0001757898) (Issuer)

    11/25/25 4:39:27 PM ET
    $STE
    Industrial Specialties
    Health Care

    $STE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Steris upgraded by Morgan Stanley with a new price target

    Morgan Stanley upgraded Steris from Equal-Weight to Overweight and set a new price target of $276.00

    7/15/25 8:30:16 AM ET
    $STE
    Industrial Specialties
    Health Care

    Jefferies initiated coverage on Steris with a new price target

    Jefferies initiated coverage of Steris with a rating of Hold and set a new price target of $263.00

    5/29/25 8:18:41 AM ET
    $STE
    Industrial Specialties
    Health Care

    Steris upgraded by Piper Sandler with a new price target

    Piper Sandler upgraded Steris from Neutral to Overweight and set a new price target of $260.00 from $230.00 previously

    10/24/24 6:28:31 AM ET
    $STE
    Industrial Specialties
    Health Care

    $STE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by STERIS plc (Ireland) (Amendment)

    SC 13G/A - STERIS plc (0001757898) (Subject)

    2/13/24 5:14:05 PM ET
    $STE
    Industrial Specialties
    Health Care

    SEC Form SC 13G/A filed by STERIS plc (Ireland) (Amendment)

    SC 13G/A - STERIS plc (0001757898) (Subject)

    2/9/24 11:49:03 AM ET
    $STE
    Industrial Specialties
    Health Care

    SEC Form SC 13G/A filed by STERIS plc (Ireland) (Amendment)

    SC 13G/A - STERIS plc (0001757898) (Subject)

    2/9/24 11:32:52 AM ET
    $STE
    Industrial Specialties
    Health Care

    $STE
    Financials

    Live finance-specific insights

    View All

    STERIS Announces Financial Results for Fiscal 2026 Third Quarter

    Total revenue from continuing operations increased 9%; constant currency organic revenue grew 8% As reported EPS from continuing operations increased to $1.96; adjusted EPS increased to $2.53Fiscal 2026 outlook maintained DUBLIN, IRELAND, Feb. 04, 2026 (GLOBE NEWSWIRE) -- STERIS plc (NYSE:STE) ("STERIS" or the "Company") today announced financial results for its fiscal 2026 third quarter ended December 31, 2025. Total revenue from continuing operations for the third quarter of fiscal 2026 increased 9% to $1.5 billion compared with $1.4 billion in the third quarter of fiscal 2025. Constant currency organic revenue growth from continuing operations for the third quarter was 8%. "We are pl

    2/4/26 4:30:00 PM ET
    $STE
    Industrial Specialties
    Health Care

    STERIS Announces Dividend of $0.63 per share

    DUBLIN, IRELAND, Jan. 28, 2026 (GLOBE NEWSWIRE) -- STERIS plc (NYSE:STE) ("STERIS" or the "Company") announced today that the Company will distribute a quarterly dividend of $0.63 per share. The dividend is payable on March 19, 2026, to shareholders of record at the close of business on February 17, 2026.   Additional information about the U.S. tax treatment of dividends, including required Forms 8937, is available at www.steris-ir.com. STERIS is a leading global provider of products and services that support patient care with an emphasis on infection prevention. WE HELP OUR CUSTOMERS CREATE A HEALTHIER AND SAFER WORLD by providing innovative healthcare and life science products and serv

    1/28/26 4:30:00 PM ET
    $STE
    Industrial Specialties
    Health Care

    STERIS to Host a Conference Call for Fiscal 2026 Third Quarter Results on February 5, 2026

    DUBLIN, IRELAND, Jan. 21, 2026 (GLOBE NEWSWIRE) -- STERIS plc (NYSE:STE) ("STERIS" or the "Company") announced today that it will host a conference call to discuss its fiscal 2026 third quarter results at 9:00 a.m. ET on February 5, 2026. The conference call can be heard live at www.steris-ir.com or via phone by dialing 1-833-535-2199 in the United States or 1-412-902-6776 internationally, then asking to join the conference call for STERIS plc. A press release detailing financial results will be issued after the U.S. market closes on February 4, 2026. For those unable to listen to the conference call live, a replay will be available beginning at 12:00 p.m. ET on February 5, 2026, either

    1/21/26 4:30:00 PM ET
    $STE
    Industrial Specialties
    Health Care

    $STE
    Leadership Updates

    Live Leadership Updates

    View All

    METTLER TOLEDO Announces Michael J. Tokich to Join Board of Directors

    Mettler-Toledo International Inc. (NYSE:MTD) announced today that Michael J. Tokich has been appointed to its Board of Directors, effective February 5, 2026. Mr. Tokich served for over 17 years as Senior Vice President and Chief Financial Officer ("CFO") at STERIS plc (NYSE:STE), a leading global healthcare and life science provider of products and services, prior to recently transitioning to the role of Senior Financial Advisor at STERIS. Mr. Tokich joined STERIS in 2000 and held various senior financial roles prior to his appointment as CFO in 2008. Roland Diggelmann, Chair of the Board, stated, "Mike is a highly accomplished executive who brings nearly two decades of U.S. public comp

    1/20/26 4:30:00 PM ET
    $MTD
    $STE
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Industrial Specialties
    Health Care

    CooperCompanies Appoints Walter M Rosebrough, Jr. to its Board of Directors

    SAN RAMON, Calif., Dec. 23, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (NASDAQ:COO), a leading medical device company, announced today that the Company's Board of Directors (the "Board") has appointed Walter (Walt) M Rosebrough, Jr. as an independent director, effective as of January 3, 2026. In connection with this appointment, the Company also has entered into a cooperation agreement (the "Cooperation Agreement") with Browning West, LP. ("Browning West"). Mr. Rosebrough will join the Board's Corporate Governance & Nominating Committee. The Board has also agreed that, by the end of 2026, it shall provide due and serious consideration for Mr. Rosebrough to be appointed Chair of the Board. In

    12/23/25 8:00:00 AM ET
    $COO
    $STE
    $VREX
    Ophthalmic Goods
    Health Care
    Industrial Specialties
    Industrial Machinery/Components

    STERIS Appoints Esther M. Alegria, Ph.D. to Board of Directors

    DUBLIN, IRELAND, May 03, 2023 (GLOBE NEWSWIRE) -- STERIS plc (NYSE:STE) ("STERIS" or the "Company") announced today that Esther M. Alegria, Ph.D. has been elected to the Board of Directors, effective today. "We are pleased to welcome Dr. Alegria to our Board," said Mohsen Sohi, Chairman of STERIS. "She brings over three decades of experience in the biopharmaceuticals industry to our Board and will be a valuable addition." Dr. Alegria is the Founder and Chief Executive Officer of APIE Therapeutics, where she leads a team focused on the development of therapeutic drugs to treat chronic and debilitating diseases. Prior to APIE, Dr. Alegria was President and Senior Executive Advisor at Catal

    5/3/23 4:30:00 PM ET
    $CDMO
    $STE
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Industrial Specialties